中关村（000931.SZ）1月16日在投资者互动平台表示，公司盐酸二氢埃托啡舌下片为全球独家I类新 药，截至目前尚未开拓海外市场。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问：公司生产的1类药二氢埃托啡，是否是创新药？ 是全球独一家生产吗？产品有无销往海外或有海外定单？ ...

北京商报讯(记者程靓)1月16日，在北京市丰台区两会新闻发布会上，中关村丰台园党工委副书记、管 委会主任张俊峰表示，"十四五"期间，丰台园经济贡献持续领跑。丰台园重点企业实现总收入5861亿 元，位列中关村示范区第三，年均增速9.1%。区域经济贡献占全区四分之一以上，"主引擎"地位稳固。 市场主体量质齐升，国家高新技术企业近2000家，较"十三五"末增长70%；专精特新"小巨人"企业数量 占全区比重高达93%，以绝对优势领跑全区，成为支撑区域升级的核心力量。 产业体系成型起势。构建了以轨道交通、航天航空两大千亿级集群为引领的"2+4"产业体系，收入规模 占丰台园比重54%。轨道交通信号控制技术国际先进，国内市场占有率达到40%以上。航天领域形成卫 星互联网先发优势同时，积极布局低空技术、智能医工等新赛道，产业发展动能不断增强。 创新生态持续优化。企业创新投入与产出大幅跃升，研发经费达148亿元，技术收入较"十三五"末提升 60%，有效发明专利近万件，是"十三五"末的1.5倍。集聚各类创新平台近120家，新增产业空间90万平 方米，建成3个中关村特色产业园，创新承载能力显著增强。 此外，营商环境迭代升级。打造" ...

Core Insights - The Fengtai Park in Beijing has shown strong economic contributions during the 14th Five-Year Plan period, with key enterprises achieving a total revenue of 586.1 billion yuan, ranking third in the Zhongguancun Demonstration Zone, and an average annual growth rate of 9.1% [1] - The region's economic contribution accounts for over one-quarter of the total district, solidifying its position as a "main engine" of growth [1] - The number of national high-tech enterprises has increased by 70% compared to the end of the 13th Five-Year Plan, reaching nearly 2,000, with "specialized, refined, distinctive, and innovative" small giant enterprises making up 93% of the total in the area [1] Economic Structure - A "2+4" industrial system has been established, led by two trillion-yuan clusters in rail transit and aerospace, which together account for 54% of the revenue in Fengtai Park [1] - The rail transit signal control technology is internationally advanced, with a domestic market share exceeding 40% [1] - In the aerospace sector, there is a first-mover advantage in satellite internet, alongside active investments in low-altitude technology and smart medical engineering [1] Innovation Ecosystem - There has been a significant increase in corporate innovation investment and output, with R&D expenditure reaching 14.8 billion yuan and technology revenue rising by 60% compared to the end of the 13th Five-Year Plan [1] - The number of effective invention patents has reached nearly 10,000, which is 1.5 times that of the end of the 13th Five-Year Plan [1] - Approximately 120 various innovation platforms have been established, with an additional 900,000 square meters of industrial space created, including three characteristic industrial parks in Zhongguancun [1] Business Environment - The business environment has been iteratively upgraded, with the "Xianfeng No. 9" service brand achieving full coverage of building enterprise services, and both the resolution rate and satisfaction rate for enterprise requests reaching 100% [2] - Significant financial empowerment has been achieved through strategic partnerships with 40 venture capital funds and the launch of multiple technology credit products in collaboration with financial institutions [2] - The first enterprise overseas training platform in the city has been established, and the international service network continues to improve [2] - The招商机制 has been continuously optimized, with a comprehensive investment attraction plan implemented to enhance information sharing, process standardization, and efficiency [2]

Group 1 - Xianghe Industrial signed a contract worth 43.1041 million yuan with China Railway 15th Bureau, accounting for approximately 6.5% of the company's projected revenue for 2024 [1] - Dayu Water-saving's subsidiary won a bid for a project valued at 133 million yuan, with a construction period of 545 days [2] - China National Materials International's subsidiary signed a contract worth 299 million Canadian dollars for engineering design and procurement services [3] Group 2 - Baoland expects a net loss of approximately 75 million yuan for 2025, compared to a loss of 58.7224 million yuan in the previous year [4] - Changhong High-tech received an administrative regulatory decision due to inadequate internal controls and improper revenue recognition [5] - Debon Stock will be suspended from trading on January 21, 2026, pending a decision on its delisting [6] Group 3 - Haitai Technology anticipates a net profit increase of 226.86% to 323.97% for 2025, with an expected profit of 51.5 million to 66.8 million yuan [7] - Fushun Special Steel expects a net loss of 770 million to 870 million yuan for 2025, compared to a profit of 112 million yuan in the previous year [8] - Rejing Bio forecasts a net loss of 210 million to 230 million yuan for 2025, compared to a loss of 191 million yuan in the previous year [10] Group 4 - Sanyou Chemical expects a net profit of approximately 91 million yuan for 2025, a decrease of about 82% compared to the previous year [11] - Lianhuan Pharmaceutical received approval for clinical trials of a new drug for benign prostatic hyperplasia [12] - Samsung New Materials anticipates a net loss for 2025, indicating a decline in operational performance [13] Group 5 - Jinggong Technology expects a net profit increase of 36.1% to 70.13% for 2025, with an estimated profit of 200 million to 250 million yuan [14] - Zhongsheng Pharmaceutical's subsidiary signed a licensing agreement for the production and commercialization of RAY1225 injection, with total payments expected to reach 1 billion yuan [15] - Hengshuai shares saw a reduction of 600,000 convertible bonds held by its controlling shareholder [16] Group 6 - Buchang Pharmaceutical plans to repurchase shares worth 60 million to 120 million yuan for employee stock ownership plans [17] - Baike Bio expects a net loss of 220 million to 280 million yuan for 2025, marking a shift from profit to loss [18] - Weishi Electronics anticipates a net profit decrease of 53.27% to 61.61% for 2025, with expected profits of 21.49 million to 26.16 million yuan [19] Group 7 - China Automotive Research expects a net profit increase of 17.85% for 2025, with a projected profit of 1.06 billion yuan [20] - Hualan Biological's controlling shareholder raised the upper limit of its shareholding plan to 86.66 yuan per share [22] - Nasda anticipates a net loss for 2025, indicating a decline in financial performance [23] Group 8 - Haizheng Pharmaceutical received a warning letter from the Zhejiang Securities Regulatory Commission for financial data inaccuracies [24] - Mengguli received an administrative regulatory decision for accounting errors in its financial reports [25] - Zhongguancun's subsidiary received acceptance for a drug application for a heart-related treatment [26] Group 9 - Hosheng Silicon Industry was ordered to correct information disclosure violations by the Zhejiang Securities Regulatory Commission [27] - Meiteng Technology expects a net profit decrease of 22.4551 million to 28.5285 million yuan for 2025, a reduction of 55.21% to 70.14% [28] - Sanwei Co. received a warning letter for financial irregularities related to related party transactions [29] Group 10 - Ganyue Expressway expects a net profit increase of 3.18% for 2025, with a projected profit of 1.32 billion yuan [30] - Xinhang New Materials plans to acquire 51% of Hairete for 12.8826 million yuan [31] - China Software anticipates a net loss of 41 million to 49 million yuan for 2025, an improvement from the previous year's loss [32] Group 11 - Rongsheng Development expects a net loss for 2025, with losses not exceeding the previous year's audited net assets [33] - Northern Rare Earth anticipates a net profit increase of 117% to 135% for 2025, with expected profits of 2.176 billion to 2.356 billion yuan [34] - Energy-saving Wind Power received renewable energy subsidies totaling 1.507 billion yuan, a 122.74% increase from the previous year [35] Group 12 - Dongzhu Ecology expects a net loss of 935 million to 1.135 billion yuan for 2025, compared to a loss of 630 million yuan in the previous year [36] - Jingneng Real Estate anticipates a net loss of 986 million to 1.315 billion yuan for 2025, compared to a loss of 109 million yuan in the previous year [37] - Hailu Heavy Industry signed new orders worth 1.941 billion yuan for 2025, with total orders on hand amounting to 3.597 billion yuan [38] Group 13 - Dalian Thermal Power expects a net loss of 92 million to 112 million yuan for 2025, compared to a loss of 146 million yuan in the previous year [39] - Jiangsu Sop expects a net profit decrease of 52.99% to 62.4% for 2025, with profits projected between 8 million to 10 million yuan [40] - Lian Technology plans to initiate preparations for issuing H-shares and listing on the Hong Kong Stock Exchange [42] Group 14 - Zhenyang Development expects a net profit decrease of 58.13% to 64.94% for 2025, with profits projected between 67 million to 80 million yuan [43] - Sheneng Co. reported a 1.7% decrease in power generation for 2025, with total generation of 57.654 billion kWh [44] - XGIMI Technology's subsidiary received a development notification from a well-known domestic automotive manufacturer [45] Group 15 - Wanhua Chemical's MDI Phase II facility resumed production after maintenance [46] - Daqing Energy expects a net loss of 1 billion to 1.3 billion yuan for 2025, with a reduction in losses compared to the previous year [47]

药品名称：盐酸普萘洛尔注射液 关于下属公司北京华素盐酸普萘洛尔注射液收到国家药品监督管理局《受理通知书》的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2026-010 北京中关村科技发展（控股）股份有限公司 关于下属公司北京华素盐酸普萘洛尔注射液收到 国家药品监督管理局《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属公司 北京华素制药股份有限公司（以下简称：北京华素）于近日收到国家药品监督 管理局（以下简称：国家药监局）签发的《受理通知书》，盐酸普萘洛尔注射 液（规格：2ml：2mg）上市许可申请获得受理，现将相关情况公告如下： 一、基本信息 剂型：注射液 规格：2ml：2mg 申请事项：境内生产药品注册上市许可 注册分类：化学药品 3 类 申请人：北京华素制药股份有限公司 受理号：CYHS2600173 结论：经审查，决定予以受理。 二、药品其他相关情况 盐酸普萘洛尔注射液临床上用于治疗心绞痛；期前收缩（室上性、室性）、 阵发性心动过速（室上性、室性） ...

Core Insights - The annual "2025 Technology Wind and Cloud List" event was held on January 15, 2026, in Beijing, focusing on the theme "Inspiring New Intelligence, Embarking on a New Journey" [1][5] Group 1: Areas of Implementation for Intelligent Agents - The implementation of intelligent agents in enterprises is categorized into three core areas: marketing and sales services, enterprise knowledge management and office efficiency, and optimization of specific business processes [3][7] - The marketing and sales services area is already productizable, while the other two areas require deeper customization based on industry characteristics [3][7] - Intelligent agents in the marketing services sector have reached a stage of widespread implementation, which is a key focus for Zhongguancun KJ [3][7] Group 2: Challenges in Implementation - The key challenges in deploying intelligent agents include adherence to business rules or SOPs, accuracy requirements, and cost-effectiveness [3][7] - Addressing these challenges necessitates advancements in technology, integration of product design with implementation effectiveness, and careful management of customer expectations and deployment sequencing [3][7] Group 3: Industry Evolution Perspective - The evolution from information technology to digitalization and then to intelligence is a long-term trend, moving towards a model of human-machine collaboration [4][8] - The future may see a shift in focus from human-centered approaches to a model centered around an absolute truth, fostering better operational states within enterprises through human-machine collaboration [4][8]

Core Insights - The annual "2025 Technology Wind and Cloud List" event was held on January 15, 2026, in Beijing, with the theme "Inspiring New Intelligence, Embarking on a New Journey" [1][5] Group 1: Areas of Application for Intelligent Agents - The implementation of intelligent agents in enterprises is categorized into three core areas: marketing and sales services, enterprise knowledge management and office efficiency, and optimization of specific business processes [3][7] - The marketing and sales services area is already productized and shows good application results through real-time front-end teams, while the other two areas require deeper customization based on industry characteristics [3][7] - The optimization of business processes has the highest difficulty due to significant industry differences [3][7] Group 2: Challenges in Implementation - Key challenges in deploying intelligent agents include adherence to business rules or SOPs, accuracy requirements, and cost-effectiveness [3][7] - Addressing these challenges necessitates not only technological advancements and effective product design but also a focus on customer expectation management and planning for implementation order [3][7] Group 3: Industry Evolution Perspective - The long-term trend is the deepening integration of informatization, digitalization, and intelligence, moving from a human-centered approach to a human-machine collaborative model [4][8] - Future operations may evolve towards a model centered around an absolute truth, fostering better business operations through human-machine collaboration [4][8]

Group 1 - The core viewpoint of the news is that two companies under Zhongguancun Development Group have successfully listed on the Hong Kong Stock Exchange, achieving the construction of an "A+H" dual capital platform [1] - Haowei Group is the first company this year to achieve "A+H" listing and is the first in the domestic CMOS image sensor (CIS) field to do so, becoming the "first stock" of image sensors in Hong Kong [2] - Haowei Group is a global semiconductor design company that has received significant funding support from Zhongguancun Capital between 2013 and 2016, which has been crucial for its development [4] Group 2 - Zhaoyi Innovation, another leading semiconductor company, has focused on chip design under a waferless manufacturing model since its establishment in 2005 and has listed on the A-share main board since August 2016; its recent Hong Kong listing marks an important step in its international strategy [5] - Zhongguancun Development Group has provided multi-round funding support exceeding 100 million yuan to Zhaoyi Innovation during its early stages, helping to address financing challenges [7] - Zhaoyi Innovation's product system covers multiple areas including Flash, niche DRAM, MCU, analog chips, and sensor chips, widely applied in consumer electronics, automotive electronics, industrial control, energy storage devices, IoT, PCs and servers, and communications [7]

近日，权威机构智能超参数发布《中国大模型中标项目监测与洞察报告 (2025)》，数据显示2025年国内 应用类大模型中标项目达4362个，市场正加速从"技术探索"向"业务落地"深化。其中，中关村科金凭借 在垂类场景的深耕优势，成功跻身"2025年应用类大模型项目中标厂商TOP10" ，同时在核心赛道"智能 客服&数字人"场景中位列厂商前三，在金融行业大模型项目中标厂商中排名第四，彰显其在大模型商 业化落地领域的标杆地位。 | 排名 | 厂商名称 | 中标项目数量 | 披露中标金额 | | --- | --- | --- | --- | | | | (个) | (万元) | | 1 | 科大讯飞 | 169 | 212874 | | 2 | 百度 | 72 | 31692 | | 3 | 火山引擎 | 50 | 29175 | | 4 | 中电信数智 | 39 | 7241 | | | 科技 | | | | 5 | 智谱 | 34 | 8344 | | 6 | 腾讯云 | 29 | 7166 | | 7 | 阿里云 | 29 | 4992 | | 8 | 中电信人工 | 24 | 1072 | | | 智能科技 ...

下一步，中关村协同创新智汇园将以此次入选为新起点，进一步深化"智能+网联+数据"的产业融合，持续推进核心技术攻 关与场景开放协同，全力建设产业生态完善、示范效应显著的大数据产业园，为安徽省数字经济与实体经济深度融合贡献重要 力量。 此次评选严格围绕产业特色、规模效应、创新应用、基础设施与服务保障等多维标准开展，旨在选拔真正具有行业引领与 示范价值的标杆园区。中关村协同创新智汇园的入选，标志着园区在智能网联方面的实践与成果，获得了省级层面的高度认 可。 目前，中关村协同创新智汇园已集聚企业80余家，包括专精特新中小企业近20家、国家高新技术企业50余家，覆盖环境感 知、决策控制、云平台、车联网-V2X、高精度地图、信息安全等全产业链环节，并落地了5G自动驾驶小巴、无人配送、V2X 测试基地等多类智能网联大数据应用场景。 本报讯 （记者李春莲） 中关村协同创新智汇园始终坚持以资质建设为发展支撑，已构建覆盖"国家级—省级—市级—区级"的四级荣誉体系，先后 荣获国家级荣誉1项（专业型国家级科技企业孵化器）、省级荣誉4项（安徽省科技企业孵化器、安徽省青年创业园、安徽省小 微企业创业示范基地、安徽省大数据产业园）、市级荣 ...